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Primary cancer cell dissemination is a key event during the metastatic cascade, but context-
specific determinants of this process remain largely undefined. Multiple reports have 
suggested that the p53 (TP53) family member p63 (TP63) plays an anti-metastatic role 
through its minor epithelial isoform containing the N-terminal transactivation domain 
(TAp63). However, the role and contribution of the major p63 isoform lacking this domain, 
〉Np63g, remain largely undefined. Here, we report a distinct and TAp63-independent 
mechanism by which 〉Np63g-expressing cells within a TGFく-rich microenvironment 
become positively selected for metastatic dissemination. Orthotopic transplantation of 
〉Np63g-expressing human osteosarcoma cells into athymic mice resulted in larger and more 
frequent lung metastases than transplantation of control cells. Mechanistic investigations 
revealed that 〉Np63g repressed miR-527 and miR-665, leading to the upregulation of two 
TGFく effectors, SMAD4 and TくRII (TGFBR2). Furthermore, we provide evidence that this 
mechanism reflects a fundamental role for 〉Np63g in the normal wound healing response. 
We show that 〉Np63g-mediated repression of miR-527/665 controls a TGFく-dependent 
signaling node that switches off anti-migratory miR-198 by suppressing the expression of the 
regulatory factor, KSRP (KHSRP). Collectively, these findings reveal that a novel microRNA 
network involved in the regulation of physiological wound healing responses is hijacked and 
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The p53 family of transcription factors, including p53 (TP53), p63 (TP63) and p73 (TP73), 
are key players in tumor development (1). The p53 gene is the prototypical human tumor 
suppressor and is mutated or lost in the majority of human cancers (1). Unlike p53, neither 
p63 nor p73 exhibits frequent somatic mutation in cancer (2,3). Nevertheless, a tumor 
suppressor role for p73 is suggested by genetic and biochemical studies, while p63 has been 
linked to tumorigenesis rather than tumor suppression (4). In the normal stratified epithelia 
p63 functions to maintain cellular regenerative proliferation and survival, and overexpression 
and/or genomic amplification of p63 is observed in a subset of human cancers (5). 
 
All three p53 family members encode proteins with highly homologous DNA binding 
domains, through which they regulate both shared and distinct subsets of transcriptional 
targets (6). Both p63 and p73 are expressed from two distinct promoters, thereby producing 
isoforms that either contain or lack the N-terminal transactivation domain (TAp63/p73 and 
∆Np63/p73, respectively) (3). Differential mRNA splicing also gives rise to multiple C-
terminal variants of both p63 and p73. In both normal epithelia and in epithelial cancers 
including head and neck squamous cell carcinoma (HNSCC), prostate and breast cancer the 
predominant p63 isoform expressed is ∆Np63α (7,8). Supporting the central role of this 
isoform, selective knockout of ∆Np63 but not TAp63 in vivo recapitulates the phenotype of 
complete p63 knockout(9-11). 
 
Regulation by MicoRNAs (miRs) is known to contribute to diverse cellular processes in both 
normal and cancer cells. While p53 is known to regulate miRs that contribute to its function, 
the identity and contribution of p63 and p73-regulated miRs are poorly understood (12).  
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We recently demonstrated that p63 itself directly regulates a subset of miRs that function in a 
feed-forward circuit to regulate p73 levels and activity (13). This finding is in keeping with an 
emerging consensus that miRs are particularly prominent within regulatory circuits 
controlling transcription factor functions. Emerging data suggest that such circuits may be 
particularly important for regulation of cellular functions associated with tumor metastasis 
(14). In the last decade, several miRs have been identified as promoters or suppressors of 
metastatic dissemination. These miRs regulate metastasis through divergent or convergent 
regulation of metastatic genes within specific pathways. The consequences of this regulation 
can be the modification of the cancer cell phenotype itself or a modification of the metastatic 
microenvironment composition (15). 
 
One such metastatic pathway potentially under the control of miRs is the TGFく pathway. 
TGFく is a ubiquitously expressed cytokine that regulates numerous biological activities in a 
wide range of tissues. In addition to its role in regulating cell development, differentiation, 
and survival, TGFく inhibits the proliferation of epithelial, endothelial, and hematopoietic cell 
lineages (16). A hallmark of neoplastic transformation is the resistance to TGFく-mediated 
cytostasis, which ultimately converts the signals produced by this cytokine into oncogenic 
activities, and particularly enhanced cancer cell invasion and metastasis. This dramatic 
modification of TGFく function underlies the adverse prognosis associated with elevated 
TGFく levels in developing carcinomas, involving their acquisition of epithelial-mesenchymal 
transition (EMT), and metastatic chemoresistant phenotypes (17). The molecular mechanisms 
whereby TGFく promotes the progression of late stage carcinomas as well as cancer cell 
invasion and metastasis remain to be elucidated, highlighting the need to understand the 
seemingly paradoxical activities of TGFく in normal and malignant cells.  
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The potential role of p63 in metastasis regulation remains poorly understood. The TAp63 
isoform was identified as a metastasis suppressor by decreasing mobility and invasion (18). 
Additionally, Adorno M et al, have described a mechanism whereby TGFく functions 
upstream to abrogate TAp63-mediated metastasis suppression through formation of a ternary 
complex involving mutant p53 and SMAD2 (19). In contrast the relationship, if any, of the 
major ∆Np63α isoform to metastasis and TGFく remain controversial. One study described 
∆Np63α as a pro-metastatic protein, while two recent contradictory studies describe 〉Np63 
isoform as pro- or anti-EMT, in a TGFく-dependent manner (18,20-22).  
 
Here we report a systemic analysis of p63-regulated miRs, which uncovered a prominent and 
selective contribution of ∆Np63α to miR-dependent control of the TGFく pathway. We show 
that ȴNp63 and TAp73, but not TAp63, control the expression of miR-527 and miR-665, two 
miRs that repress the central TGFく regulators SMAD4 and TGFBR2. We provide evidence 
that this p63-mediated pathway is linked to control of normal wound healing through TGFく-
dependent regulation of the KSRP/ miR-198 axis. In tumors, we show that this regulatory 
network orchestrates the metastatic dissemination of tumor cells within the TGFく-containing 
microenvironment. Taken together, our findings implicate a miR-dependent circuit involved 
in normal wound healing via ∆Np63α as a key mediator of TGFく -induced metastatic 
dissemination. 
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Materials and Methods 
Tumor cell line and patient tumor material 
The cell lines JHU-029, was the generous gifts of David Sidransky (Johns Hopkins 
University). This line was maintained by the MGH Center for Molecular Therapeutics cell 
line bank and underwent high-density single nucleotide polymorphism (SNP) typing, 
revealing that each was unique compared with > 800 other banked lines. Stocks of JHU-029 
used in this study express no wild-type p53 due to a frameshift mutation in p53 codon 108 
that results in premature truncation. Tetracycline-inducible HA-TAp73β cells were 
established in JHU-029 using the TREx plasmid system (Invitrogen). Cells were maintained 
at 37°C with 5% CO2 in either RPMI (Lonza) supplemented with 10% FBS, penicillin, and 
streptomycin. 
The human osteosarcoma cell lines MNNG/HOS (young female high grade osteosarcoma 
from femur origin transformed in vitro by N-methyl-N'-nitro-N-nitrosoguanidine treatment), 
were purchased from the American Type Culture Collection and maintained in RPMI 1640 
(Lonza) supplemented with 10% fetal bovine serum and 2mmol L-1 L-glutamine. All cell lines 
were cultured in a humidified 5% CO2/air atmosphere at 37oC.  The cell line was maintained 
by our University cell facility. Genetic characteristics were determined by PCR-single-locus-
technology by Eurofins compagny using Promega, PowerPlex 21 PCR Kit.  All cell lines 
were passaged for less than 3 months and tested in July 2015. 
Osteosarcoma cell lines subpopulations were obtained at the time of diagnostic biopsy (B) or 
after surgical resection of lung metastasis (M), in patients diagnosed with osteosarcoma at the 
Hospital of the University of Navarra (Clínica Universidad de Navarra, CUN, Pamplona, 
Spain). The clinical features of clinical samples are available in supplemental Table 1. 
Samples were obtained following patient informed consent, and after ethical approval by the 
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Navarra University Hospital Ethics Committee. All subpopulations were thoroughly 
characterized as previously described (Patiño-García et al. Clin Cancer Res).  
Micro-RNA micro Array analysis 
For each sample, 2たg of Trizol extracted total RNA were purified using the RNeasy Mini 
Cleanup Kit (Qiagen). After having passed sample quality control on the Bioanalyser2100, 
the samples were labelled using the miRCURY™ Hy3™/Hy5™ power labelling kit and 
hybridized on the miRCURY™ LNA Array (v.10.0) (Exiqon). Spike-in controls were added 
in various concentrations covering the full signal range, in both Hy3 and Hy5 labelling 
reactions giving the opportunity to evaluate the labelling reaction, hybridization and the 
performance of the array experiment in general. The quantified signals (background 
correction) were normalized using the global Lowess (LOcallyWEighted Scatterplot 
Smoothing) regression algorithm. The diagram only represent the microRNAs that passed the 
filtering criteria across samples; Fold Change > 1.50. The microarray data discussed in this 
publication have been deposited in NCBI Gene Expression Omnibus (GEO Series accession 
number GSE25524). 





All the pre-miRTM and anti-miRTM were obtained from Ambion and tranfected at a final 
concentration of 30nM using the siPORTNeoFX Transfection Agent (Ambion) according to 
the manufacturer’s protocol. The pre-miRTM and anti-miRTM Negative Controls used are 
random sequences that have been tested in human cell lines and tissues and validated to not 
produce identifiable effects. 
Transient transfection of TAp73b and ǻNp63Į 
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Both TAp73く and 〉Np63g sequences were inserted in pcDNA3 vector (Invitrogen). 2µg of 
DNA were transfected using FuGENE® HD Transfection Reagent (Promega) according to 
the manufacturer’s protocol. We used pcDNA3 empty vector as a control. These assays were 
all performed as described (13) 
Cell proliferation 
JHU-029 cells (2 x 103/well) were plated in 0.1 mL RPMI 1640 with 10% FBS and treated 
with pre-miRs and anti-miRs at indicated concentration. 72h after transfection a solution of 
WST-1 was added to the wells. Cell proliferation was assessed by optical density 
measurement at 470nm with Victor2 1420 (MultilabelCounter, Perkin Elmer). The viability 
percentage is calculated by: OD at 470nm with indicated pre-miR/ OD at 470nm with pre-
miR control x 100. Each assay was repeated in triplicate.  
Western blotting analysis 
Samples containing equal amounts of protein (depending on the antibody, 20-50µg) from 
lysates of cultured cell lines underwent electrophoresis on SDS-polyacrylamide gel and were 
transferred to PVDF membranes. The membranes were blocked in 3% BSA-PBS-0.05% 
Tween at room temperature for 1h and blots were probed overnight at 4°C with primary 
antibodies (TくRII, 1:1,000; Abcam), (SMAD4, 1:500; Santa Cruz Biotechnologies), (SMAD3 
and P-SMAD3, 1:1,000; Cell Signaling Technologies), (p63, 1:1,000; Sigma-Aldrich), (p73, 
1:500; Calbiochem) or GAPDH (1:2,000; Cell signaling) to detect proteins of interest. After 
incubation, the membranes were washed 3 times with washing buffer (PBS containing 0.05% 
Tween) for 5min. Membranes were then incubated for 1h with 1:10,000 diluted secondary 
antibodies (Santa Cruz Biotechnologies, Santa Cruz, CA) at room temperature. Specific 
proteins were detected using G-Box (Syngene, Cambridge, UK) after washing. 
Quantitative Reverse Transcription-PCR 
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Total RNA was extracted from cultured cells, human biopsies or xenografts using TRIreagent 
(Invitrogen Life Technologies). Total RNA was reversed transcribed using the ThermoScript 
RT-PCR System (Life Technologies). Real-time monitoring of PCR amplification of 
complementary DNA (cDNA) was performed using DNA primers (primers sequences are 
available in Supplementary Table 2) on CFX96 real-time PCR detector system (Bio-Rad, 
Marnes la Coquette, France) with SYBR PCR Master Mix buffer (Bio-Rad). Target gene 
expression was normalized to the average B2M and GAPDH levels in respective samples as 
an internal standard, and the comparative cycle threshold (Ct) method was used to calculate 
relative quantification of target mRNAs. Each assay was performed in triplicate. 
Quantitative Reverse Transcription-PCR miR 
A specific RT was performed for each miR from 100 ng of total RNA, using a specific stem-
loop RT primer (50 nM) and the MultiScribe Reverse transcriptase (Applied Biosystems). The 
RT conditions were as follows: 30 minutes at 16°C followed by 30 seconds at 20°C, 30 
seconds at 42°C, 1 second at 50°C for 60 cycles, and finally 5 minutes at 85°C. Mature miRs’ 
expression levels were measured by real-time qRT-PCR using the SYBR PCR Master Mix 
buffer (Bio-Rad) and a CFX96 real-time PCR detector system (Bio-Rad). The expression of 
each gene was normalized to the small nuclear U6B RNA as a reference. All experiments 
were performed in triplicate. Primer sequences for the RT and qPCR are available in 
Supplementary Table 3 and 4 respectively. 
Lentiviral and retroviral production and mRNA QRT-PCR 
P63 shRNA lentiviral particles were produced by transfection of required viral plasmids (4µg 
of each: RSV-RRE, RGR, VSV-G and 4 µg of p63 All isoforms shRNA; p63Allsi; or 4µg of 
GFP shRNA; GFPsi) following the manufacturer’s protocol (CalPhos Transfection Kit; 
Clontech) in HEK 293 T cell line. HEK 293T were cultured in DMEM medium enriched with 
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10%FBS and 1X non essential amino acids (Lonza). JHU-029 cells were infected with HEK 
293T supernatants (with GFPsi as a control or p63Allsi) and selected by antibiotic resistance 
(puromycin, 1µg/mL) for several weeks. P63 All isoforms-shRNA targeted sequence is 5’-
GGGTGAGCGTGTTATTGATGCT-3’. P63-directed shRNA was validated not to cross react 
with p53 or p73 (13). Primer sequences for mRNA QRT-PCR validation are shown in Table 
2. 
3UTR Reporter assays 
50,000 cells were seeded in 24-well plates and were transfected with the indicated reporter  
constructs depending on the different conditions. Lysates were prepared at 48 hours after 
transfection, and luciferase activity was measured using the Dual Luciferase Reporter Assay 
system (Promega) and a luminometer (MicroLumat Plus, EG&G Berthold). 
For PAI-1 reporter assay, cells were transfected with the reporter vector ((CAGA)9-lux) and 
pRL SV40 (containing Renilla luciferase, Promega) together with TAp73く, 〉Np63g or pre-
miRs following manufacturer’s recommendation (siPORT™ NeoFX™ Transfection Agent, 
Invitrogen). (CAGA)9-lux reporter vector was generated using pGL3-basic vector (Promega) 
where 9 repetitions of the CAGA box sequence were inserted between BglII and HindIII 
restriction sites.  
From the MNNG/HOS cell line cDNA, two fragments of the SMAD4 3’UTR (90bp-
1900bp and 1900bp-4055bp; primers sequences are in supplemental table 5) were separately 
cloned into pMIR-REPORT™ Luciferase vectors (Ambion) using the Platinum® Taq DNA 
Polymerase High Fidelity (Life technologies). Each fragment was cloned downstream of the 
Firefly Luciferase between HindIII and SpeI restriction sites.  
 For Smad4 3’UTR reporter assays, cotransfection with 10ng of either control reporter vector 
(pMIR control, Ambion), UTR-reporter vector (pMIR SMAD4 3’UTR) or mutated UTR-
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reporter vector (pMIR mutated SMAD4 3’UTR) all together with pre/anti-miRs control, 527 
or 371-5p (15µM) and 25ng of pRL SV40 (Promega) was performed.  
For psi-check2 TȕRII 3’UTR reporter assays, cells were cotransfected with control 
reporter vector (psi-ckeck2 control, Promega), UTR-reporter vector (psi-check2 TȕRII 
3’UTR) or mutated UTR-reporter vector (psi-check2 mutated TȕRII 3’UTR) together with 
pre/anti-miRs control, 527, 665 and 371-5p (15µM) was done.  
Psi-check2 TくRII 3’UTR was a kind gift from Dr. Ioanna Keklikoglou (German Cancer 
Research Center (DKFZ), Heidelberg, Germany) where 3'UTR of the TȕRII gene was inserted 
between XhoI and NotI sites of the psi-check2 vector.  
TȕRII and SMAD4 3UTR site directed mutagenesis 
According to the TargetScan database miR-527 recognizes two putative sequences within the 
SMAD4 3’UTR and miR-665 recognizes two putative sequences within the TȕRII 3’UTR 
(supplemental figure 2).     
Mutant seed binding sequences were created with Quickchange lightning Multi site-Directed 
Mutagenesis kit (Agilent technologies, Inc) according to the manufacturer’s indications. 
Mutagenic primers were randomly designed with the web-based Quickchange Primer Design 
Program (supplemental table 5). For 3’UTR SMAD4 fragment 1 and fragment 2 a single seed 
sequence was mutated. For 3’UTR TȕRII 2 seed sequences were mutated (supplemental figure 
2).   
Migration and invasion tests 
To evaluate migration ability, JHU-029 or MNNG/HOS cell lines were transfected with 
Tap73く, 〉Np63g and control vectors or indicated pre-miRs/anti-miRs. After 24h of 
transfection cells were starved during 5 hours with RPMI 1640 supplemented with 1% FBS 
on March 18, 2016. © 2016 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 17, 2016; DOI: 10.1158/0008-5472.CAN-15-2317 
12 
 
and then pre-treated or not with 5ng/mL TGFく (R&D systems). All different conditions were 
trypsinized and treated or not with 5ng/mL TGFく before being seeded on the upper side of a 
Transwell chamber (Falcon) on a porous transparent polyethylene terephthalate (PET) 
membrane (8-たm pore size). Different cell densities were used depending on the experiment 
to increase or decrease cell migration. Indeed, to be able to observe an increased cell 
migration in our experimental conditions, we should not already have a saturated migration in 
our control condition. The percentage migration increase variation between the different 
control conditions (pre-miR Ct and anti-miR Ct) is voluntarily set up (by cell confluence 
variation) to facilitate the observation of either an increase or a decrease cell migration in 
presence of TGFく. The lower chamber of the transwell was filled with growth medium 
containing 10% FBS. After 24 hours of incubation, cells on the upper side of the filters were 
mechanically removed and cells migrated to the lower side were fixed (with glutaraldehyde 
10%), stained (with violet crystal 0.1%), and counted. Five random fields were analyzed for 
each chamber. 
Matrigel-coated transwell were used for invasion assay (50ng Matrigel/well). After 24 h 
incubation, cells that had invaded to the lower surface of membrane were fixed, stained, and 
counted. Five random fields were analyzed for each chamber.  
Wound-healing test 
50x103 JHU-029 cells were seeded in 24 well-plate and transfected with Tap73く, 〉Np63g and 
control vectors or indicated pre-miRs/anti-miRs. 24h after transfection cells were starved 
during 5 hours with RPMI 1640 supplemented with 1% FBS and then treated or not with 
5ng/mL TGFく. 24h later wells were confluent and scratches were performed. Cell migration 
was recorded during 24h every 10 minutes at fixed points and not recovered areas were 
calculated. 
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The presence of MMP-2 and MMP-9 in serum-free conditioned media was analyzed by 
zymography in 10% sodium dodecyl sulfate–polyacrylamide gels containing 1 mg/mL gelatin 
(Sigma-Aldrich). After removal of sodium dodecyl sulfate with Triton X-100, neutral protease 
activity was revealed by incubation of the gels for 48 hours at 37°C in 50mM Tris buffer (pH 
7.4) containing 2 mM CaCI2, followed by staining in 0.05% Coomassie blue in an aqueous 
solution containing 20% isopropanol and 10% acetic acid. Pictures were taken using G-Box 
(Syngene, Cambridge, UK). 
Animal Treatment 
All procedures involving mice [their housing in the Experimental Therapeutic Unit at the 
Faculty of Medicine of Nantes (France) and care, the method by which they were anesthetized 
and killed, and all experimental protocols] were conducted in accordance with the institutional 
guidelines of the French Ethical Committee (CEEA.PdL.06). Mice were anesthetized by 
inhalation of of isoflurane/air (1.5%, 1 Lmin-1). Tumor volume was measured 3 times weekly 
and tumor volume was calculated by using the formula: length x (thickness2) / 2. Data points 
were expressed as average tumor volume ± SEM. 
ȴNp63g-MNNG/HOS: MNNG/HOS cells were transiently transfected with either pcDNA3 
empty vector or pcDNA3-〉Np63g (Invitrogen) following the manufacturer’s protocol 
(FuGENE® HD Transfection Reagent, Promega). Cells expressing the insert were selected by 
antibiotic pressure (2mg/mL geneticin) for several weeks. MNNG/HOS osteolytic xenograft 
model was induced by paratibial injection of 1×106 of either control or 〉Np63g overpressing 
human MNNG/HOS cells in five weeks-old female athymic nude mice (Harlan Sprague-
Dawley, Inc.). Tumor volumes were monitored until a maximum of 2500 mm3. Tumor and 
metastasis samples were collected to analyze gene expression by RT-qPCR. 
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Pre-miR injection: HOS osteolytic xenograft model was induced by an i.m. injection of 1.5 × 
106 human HOS LucF GFP cells next to the tibia of five week-old female athymic nude mice 
(Harlan Sprague-Dawley, Inc.), leading to a rapidly growing tumor in soft tissue with 
secondary contiguous bone invasion. Once palpable tumors, mice were randomly assigned to 
pre-miR control or pre-miR-527 or pre-miR-665. When tumors reached 200mm3, pre-miRs 
were injected at a 50nM concentration every 2 days. The pre-miRs are injected directly into 
the tumor volume. A total of 20たl at 50nM were injected in 4 different locations for each 
tumor. Each experimental group consisted of 8 mice. It is important to note that in our model 
the baseline metastatic rate depends on the number of cells initially used for para-tibial 
injection. Thus, different cell numbers injected accounts for the different baseline metastatic 
rates shown in Figure 5 and Figure 6. 
When tumor volume reached ≥10% of body weight, mice were sacrificed prior to an 
intraperitoneal injection of luciferine substrate (0.12 mg D-luciferine/mg mouse; Interchim) to 
evaluate lung metastasis by bioluminescence (NightOwl BERTHOLD LB981). Tumor and 
metastasis samples were collected to analyze gene expression by RT-qPCR. 
Statistical analysis 
For each experimental datapoint, the SEM from replicate experiments was calculated as noted 
in the legends and is shown as error bars. All error bars show SEM for at least triplicate 
measurement from representative experiments. The mean ± SEM was calculated for all 
groups and compared by two-tailed paired Students t test or by ANOVA, with the Bonferroni 
multiple comparisons test for post-hoc analysis. Prism 3.0 software was used for all statistical 
analysis.  
on March 18, 2016. © 2016 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 





A subset of microRNAs regulated selectively by 〉Np63 target the TGFく pathway 
Expression of the different isoforms of p63 seems to be correlated with the metastatic 
potential of human cancers including squamous cell carcinoma (SCC) (23-26), prostate cancer 
(27), bladder cancer (28) and some breast cancers (29). To identify miRs regulated by p63 we 
ablated endogenous p63 expression by lentiviral RNA interference, followed by global miR 
expression profiling using the Exiqon Locked Nucleic Acid (LNA) Platform (Figures 1A and 
1B). We performed this initial experiment in JHU-029 squamous cell carcinoma (SCC) cells, 
a human tumor-derived line that expresses high levels of endogenous 〉Np63g, which is the 
major p63 isoform expressed in both normal basal epithelial cells and the majority of human 
SCCs (8,30). At 48 hours a significant fraction of miRs identified as reproducibly regulated 
by p63 were upregulated following p63 knockdown, consistent with the established ability of 
the major enodogenous ∆Np63α isoform to function as a transcriptional repressor (Figure 1B; 
the full list of significantly regulated miRs is provided in Supplemental Figure 1A) (8,31). 
 
Remarkably, examination of predicted target genes of these p63-regulated miRs using a 
combination of in silico resources (TargetScan, MicroCosm, DianaLab and miRANDA) 
revealed that four of the sixteen significantly upregulated miRs (miR-527, miR-665, miR-
371-5p and miR-583) were all predicted to have targets in the TGFく pathway including 
TGFBR2 and SMAD4 (Figure 1C and Supplemental Figure 1A) (32,33). Because p63 and p73 
are known to regulate a common subset of genes, we performed direct validation of p63 and 
p73-dependent regulation of these four endogenous miRs (Figure 1D and 1E) (8,34). For p63 
we used the same lentiviral RNA interference approach employed for the array analysis, then 
validated directly by qPCR the four miRs as repressed by endogenous ∆Np63. In order to 
on March 18, 2016. © 2016 American Association for Cancer Research.cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 17, 2016; DOI: 10.1158/0008-5472.CAN-15-2317 
16 
 
determine whether TAp63 isoforms regulated these endogenous miRs, we used cells 
expressing tetracycline (tet)-inducible TAp63g; no miR regulation was observed 
(Supplemental Figure 1B). In order to test p73-dependent miR regulation we performed the 
same experiment using tet-inducible TAp73β, a major p73 isoform expressed in epithelial 
cells (35) (∆Np73 being not expressed in our SCC model, it appeared not relevant to study its 
implication in this network). Induction of TAp73β mRNA is detectable within one hour 
following addition of tetracycline in these cells (Supplemental Figure 1C), and induction of 
each of the four miRs was also observed at this early time point. As a control we tested up-
regulation of the direct p73 transcriptional target gene PUMA, which was coincident with 
p73-dependent miR regulation (Figure 1E and Supplemental Figure 1C). Thus, each of these 
miRs is selectively regulated by ∆Np63 and TAp73β, but not by TAp63 isoforms.  
 
We then tested the ability of p63/p73 and their regulated miRs to control the TGFく pathway 
(Figure 1C), employing the Smad3/4-specific reporter construct (CAGA)9-lux (36). This 
reporter includes 9 copies of the SMAD3/4 biding motif fused to luciferase. Co-transfection 
of the reporter with the corresponding synthetic miR duplexes in each case, except for miR-
583, inhibited TGFく-induced luciferase expression relative to the control reporter lacking the 
SMAD3/4 biding motif. Since the array-based analysis was not validated experimentally for 
miR-583, this miR will no longer be part of the study (Figure 1F). Consistent with our 
proposed model for p63/p73-dependent regulation of this pathway (Figure 1C), ectopic 
〉Np63g expression, which decreases expression of these endogenous miRs, stimulated the 
TGF-く induced luciferase reporter expression. This effect was abolished by the introduction 
of a single point mutation in 〉Np63g, R304W, which abrogates the ability of p63 to bind to 
DNA, emphasizing the role of direct DNA binding in this regulatory process (Figure 1G)(37). 
The role of endogenous 〉Np63g in this pathway was shown through knockdown experiments, 
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which led to a decrease in TGFく-dependent luciferase reporter induction (Supplemental 
Figure 1D). Finally, ectopic expression of TAp73β, which increases the expression of these 
endogenous miRs, led to an inhibition of TGFく-induced luciferase expression compared to 
control (Figure 1G). 
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miR-527 and miR-665 repress Smad4 and TくRII, respectively 
Two predicted seed binding sequences for miR-665 and one for miR-371-5p are present 
within the TȕRII 3’UTR, and two predicted seed sequences for miR-527 are present within the 
SMAD4 3’UTR (Supplemental Figure 2A, B). Thus, in order to validate the predicted TGFく 
pathway proteins targeted by miR-527, miR-665 and miR-371-5p, we first performed 3’UTR 
reporter assays. Using a TȕRII 3’UTR reporter construct, we validated the miR-665 as a 
robust repressor of TȕRII, and eliminated miR-371-5p from the potential candidates 
(Supplemental Figure 2C). To address direct SMAD4 and TȕRII regulation by miR-527 and 
miR-665 respectively, we introduced point mutations within these 3’UTR reporter constructs, 
then co-transfected these constructs with miR mimics (also called pre-miRs) (Supplemental 
Figure 2A, B). As predicted, in both cases miR-mediated down regulation of the 3’UTR 
reporter was completely abolished when a reporter containing the mutant UTR was used 
instead (Figure 2A). Of note, the long size of the SMAD4 3’UTR forced us to divide it in two 
smaller segments and to make two reporter constructs; this revealed to us that only the second 
binding site for miR-527 within the SMAD4 3’UTR was active (Figure 2A). To test the 
endogenous miR regulation, we co-transfected anti-miRs into SCC cells with either the wild 
type or mutant UTR reporter. Consistent with our model, 527 and 665 anti-miRs mediated up-
regulation of the SMAD4 and TȕRII 3’UTR constructs, respectively (Supplemental Figure 
2D). 
 
We next tested effects on the endogenous mRNA levels for SMAD4 and TGFBR2, performing 
ectopic expression of microRNAs with pre-miRs. In addition, we tested the contribution of 
the endogenous miRs using an anti-miR strategy. As predicted, transfection of the two miR 
mimics suppressed the endogenous SMAD4 mRNA level (Figure 2B), while expression of 
specific anti-miRs caused a significant increase in endogenous SMAD4 mRNA for miR-527 
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and miR-665 but not for miR-371 (Supplemental Figure 2E). For TくRII, only the miR mimic 
for miR-665 was able to repress endogenous TȕRII mRNA level (Figure 2B) and only the 
anti-miR-665 increased the endogenous TȕRII mRNA level (Supplemental Figure 2E). Of 
note, these experiments confirmed again that miR-371-5p cannot regulate either SMAD4 or 
TȕRII, so we discarded it from our list of potential miRs regulating the TGFく pathway. 
Because miRs can also be translational regulators, we next evaluated the effects of the 
endogenous miRs using anti-miRs followed by western blot. These experiments confirmed 
miR-527 as a regulator of SMAD4 and miR-665 as a regulator of TくRII at the protein level 
(Figure 2C). As a validation of our model and of the TGFく pathway regulation, we performed 
western blots for the endogenous phosphorylated form of SMAD3 (P-SMAD3) after 
treatment with TGFく. Indeed, in control conditions, we observed an increase in P-SMAD3 as 
a result of TGFく treatment (Figure 2D). After transfection of the respective pre-miRs and 
anti-miRs, only those corresponding to miR-665 were able to regulate the phosphorylation of 
SMAD3 following TGFく treatment. This finding is expected given that only this miR has a 
target upstream of SMAD3 in the TGFく pathway, namely TくRII (Figure 2D). This result has 
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〉Np63g and TAp73く regulate Smad4 and TくRII  
According to our model, if 〉Np63g and TAp73く regulate miR-527 and miR-665 controlling 
SMAD4 and TȕRII, then the modulation of these factors should impact the level of SMAD4 
and TくRII and consequently the TGFく response in the cells. This hypothesis was first tested 
by qPCR, which showed that SMAD4 but not SMAD7 expression was specifically repressed 
by ectopic expression of TAp73く or knock-down of endogenous p63 (Figure 3A and 
Supplemental Figure 3A). The same regulation was observed for TȕRII (Figure 3A and 
Supplemental Figure 3). As predicted by our model, the principal final targets of the pathway, 
CTGF and PAI-1 were also regulated in the same way (Figure 3A and Supplemental Figure 
3). The effect on PAI-1 was also confirmed in the MNNG-HOS cell line (Supplemental 
Figure 3B). The ectopic expression of 〉Np63g, described as a repressor of our miRs of 
interest, induced as expected the expression level of SMAD4, TȕRII, CTGF and PAI-1 (Figure 
3B). Of note, we also observed the induction of TȕRI, which is not a predicted target of these 
miRs but which supports functionally the over-expression of TȕRII. Furthermore, the protein 
levels of SMAD4 and TくRII analyzed by western blot were also consistent with our model. 
Indeed, ablation of endogenous p63 and p73 overexpression both repressed SMAD4 and 
TくRII protein levels and also repressed the phosphorylation of SMAD3 following TGFく 
treatment (Figure 3C). The effect of 〉Np63g overexpression was then evaluated in the 
MNNG-HOS osteosarcoma cell line model lacking this protein isoform. As expected, we 
observed an increase of the SMAD4 and TくRII protein levels and also a strong increase of the 
phosphorylation of SMAD3 following TGFく treatment (Supplemental Figure 3C). 
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The 〉Np63g and TAp73く -regulated miR network controls TGFɴ-induced migration 
We first tested the functional relevance of our model using multiple independent migration 
assays. The pro-migration properties of TGFく were assessed using a boyden chamber test. 
We first transfected pre-miRs for our two miRs of interest. Both pre-miRs corresponding to 
miR-527 and miR-665 decreased migration induced by TGFく, from 760% to 521% and from 
760% to 191%, respectively (Figure 4A) while those pre-miRs do not affect cell viability at 
all under the same experimental conditions (Supplemental Figure 4A). 
We then performed the same experiment in presence of 〉Np63g and TAp73く. After 24 hours 
of TGFく treatment at 5ng/ml concentration, we observed a 10% increase in migration 
compared to control conditions. As predicted by our molecular analysis, ectopic expression of 
TAp73く decreased global migration by 43% (Figure 4B). In contrast, the expression of 
〉Np63g increased strongly the effects of TGFく as indicated by an increase in migration from 
10 to 480% of the untreated conditions. Interestingly, without TGFく treatment the expression 
of 〉Np63g seems to slightly decrease the basal migratory potential of the cells, as previously 
noted (Figure 4B) (18). Direct evidence showing that 〉Np63g regulates TGFく signaling via 
downregulation of miR-527 and miR-665 is provided by the abrogation of the pro-migration 
potential of 〉Np63g following overexpression of miR-527 and miR-665 Figure 4B). 
Accordingly, we also observed by Western Blot that overexpressing these miRs abrogated the 
effects on SMAD4 caused by 〉Np63g expression (Supplemental Figure 4B). Direct evidence 
showing that TAp73く regulates TGFく signaling via upregulation of miR-527 and miR-665 is 
provided by the abrogation of the anti-migration potential of TAp73く following anti-miR-527 
and 665 transfection (Supplemental Figure 4C). Finally, we validated the pro-migration 
potential of TくR2 in the presence of TGFく and the inhibition of this effect by the miR-665 
(Supplemental Figure 4D). 
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Of note, the difference in the response to TGFく treatment between the respective controls of 
Figure 4A and 4B is due to the intentional difference in the cell number plated, which 
depended on the experimental hypothesis (increased or decreased migration). 
 
The migration potential of the cells in the presence of TGFく was also tested using an in vitro 
wound-healing assay, also called a scratch assay. Ectopic expression of TAp73く decreased the 
cell migration potential by about 22% compared to control, while expression of 〉Np63g 
increased it by more than 22% (Figure 4C). We then tested the contribution of these miRs 
directly using pre-miRs and anti-miRs. Overexpression of pre-miR 527 and 665 decreased the 
cell migration potential by about 10% and 45%, respectively, compared to the anti-miR 
control, while overexpression of anti-miR 527 and 665 increased it by more than 2% and 
10%, respectively (Figure 4D and E 4). Globally, those data support the pro-migratory 
potential of endogenous p63 and the anti-migratory effect of endogenous miR-527 and miR-
665, in a TGFく-rich micro-environment context.  
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〉Np63g induces TGFɴ-mediated metastasis in vivo 
Because we demonstrated in vitro that 〉Np63g increases cell migration in presence of TGFく, 
we wished to verify whether 〉Np63g could increase in vivo the metastatic potential of tumor 
cells in a physiological context where TGFく is both present and important. One such in vivo 
model is osteosarcoma, a primary bone tumor. This type of tumor recruits osteoclasts and 
thereby induces abnormal bone resorption, which in turn releases growth factors including 
TGFく from the bone matrix and stimulates tumor proliferation and potentially metastasis 
dissemination (38-40). In this way, osteosarcoma cells establish a vicious cycle of bone 
resorption and tumor growth in which TGFく has been shown to play a role (38).  
 
To study the influence of 〉Np63g on tumor cell metastatic potential in presence of TGFく, we 
used the human osteosarcoma cell line MNNG/HOS. An important characteristic of the 
MNNG/HOS cells for these experiments is their very low 〉Np63g expression level, providing 
us the opportunity to directly assess the contribution of increased 〉Np63g through stable 
ectopic expression of this protein (Figure 5A). We first validated in vitro that repression of 
miRs 527 and 665 was observed following overexpression of 〉Np63g (Supplemental Figure 
5A). Indeed, we observed an increased sensitivity of the p63-expressing MNNG/HOS to the 
pro-migratory potential of TGFく (Figure 5B). The same result was observed in an 
experiment-assessing invasion through matrigel at the bottom of a boyden chamber. In 
presence of TGFく, the invasion of the p63-expressing MNNG/HOS increased by 85% 
whereas in the same conditions, the control cells increased their invasion by only 9% (Figure 
5B). The matrix metalloproteinase (MMPs) are proteases, activated by the TGFく pathway, 
capable of degrading multiple extracellular matrix proteins. The pro-invasive potential of 
〉Np63g in presence of TGFく could be partially explained by an increased activity of MMP-9 
as demonstrated by our zymography experiment (Supplemental Figure 5B).  Taken together, 
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these in vitro observations validate our hypothesis that 〉Np63g increases TGFく-dependent 
migration and invasion.  
 
An in vivo evaluation of our hypothesis was then performed using a human xenograft model 
involving MNNG/HOS cells that recapitulates features of the human disease (40). We 
injected control MNNG/HOS cells or their 〉Np63g-expressing counterparts (1 to 1.5 million 
cells) paratibially into athymic mice. Importantly, no significant difference in orthotopic 
tumor growth was observed between control and p63-expressing MNNG/HOS following 
injection (Figure 5C). At 65 days following injection, the animals were sacrificed, the lungs 
dissected and the number of metastasic nodules evaluated using an optical microscope. We 
observed a remarkable increase in the number of lung metastatic nodules in mice injected 
with 〉Np63g-expressing MNNG/HOS compared to the control counterparts (an average of 
4.9 vs 0.25 metastatic nodules/mouse respectively) (Figure 5D). Moreover, the metastatic 
nodules from 〉Np63g-expressing tumors were not only more numerous but also larger 
(Figure 5D). Notably, the analysis of the orthotopic tumors at the end of the experiment 
confirmed that after 65 days the transfected MNNG/HOS were still overexpressing 〉Np63g 
relative to control cells by 7-fold (Figure 5E). Even more dramatic was the expression of 
〉Np63g in the metastatic lesions, which was more than 60-fold compared to the control 
metastases. This finding suggests strong selection for 〉Np63g expression during the 
metastatic process. Similarly, a higher level of 〉Np63g was also observed in metastases than 
in the respective orthotopic tumors (Figure 5F). Moreover, as predicted by our in vitro data, 
the metastases showed a strong decrease in endogenous miR-527 and miR-665 expression 
levels (Figure 5F). Finally, in this same group of mice harboring a 〉Np63g-overexpressing 
tumor, the orthotopic tumors that gave rise to metastases expressed a higher level of both 
SMAD4 and TȕRII compared to orthotopic tumors that did not metastasize (Figure 5G). The 
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protein level of SMAD4 and P-SMAD3 (as a readout of TくR2 activity) were evaluated by 
immunohistochemistry. We observed in the tumors that gave rise to metastasis both a larger 
area of cells expressing SMAD4 and the presence of proliferative tumor cell follicles 
harboring nuclear P-SMAD3 (Supplemental Figure 5C). 
 
We then validated the relevance of this endogenous miR/TGFく pathway in osteosarcoma 
patient samples. We obtained from the University of Navarra 6 pairs of osteosarcoma primary 
tumors and their respective lung metastasis biopsy specimens. qPCR analysis revealed a 
decreased level of miR-527 and miR-665 in the metastases and a concomitant increase of 
SMAD4 and TȕRII (Supplemental Figure 5D). Collectively, these data support the pro-
migratory potential of 〉Np63g through its regulation of the endogenous miR-527/miR-
665/Smad4/TくRII network in an in vivo TGFく-rich microenvironmental context. 
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miR-527 and miR-665 regulate metastatic dissemination in vivo 
We next evaluated directly the metastasis regulation potential of miR-527 and miR-665 in 
vivo through injection of the respective pre-miR constructs into osteosarcoma orthotopic 
tumors. As noted, this type of tumor was selected for its metastatic dissemination sensitivity 
to TGFく (40). Orthotopic tumors were generated by paratibial injection of 1.5 million 
MNNG/HOS cells expressing both luciferase and GFP (41). At 200mm3 of tumor volume, 
mice were treated every 48h with 50nM pre-miR control (miRct-group) or pre-miR-527 
(miR-527 group) (Figure 6A). No differences in primary orthotopic tumor growth were 
observed between miR-527 and miR-665-treated tumors versus the control group (Figure 6B). 
At the tumor volume endpoint (2500mm3), the average number of lung metastases for miR-
527, miR-665 or the control group were evaluated both visually and using bioluminescence 
imaging of lungs after sacrifice (Figure 6C, D). Mice injected with miR-527 and miR-665 
demonstrated a significant reduction of lung metastatic nodules. To credential the mechanism 
of this effect a gene expression analysis was then performed on biopsies from the control and 
the miR-injected groups. We first validated the efficiency of the miR injection into the 
orthotopic tumor. Indeed, qPCR analysis revealed a seven and a two-fold increase in miR 
expression in the orthotopic tumor from the miR-527 and miR-665-treated group, respectively 
(Figure 6E-F). In agreement with our model attributing anti-metastatic potential to miR-527 
and miR-665, we observed a lower level of miR-527 or miR-665 in the metastatic nodules 
compared to the orthotopic tumor, and this difference was reflected functionally in a higher 
level of SMAD4 or TȕRII, respectively, in the metastatic lesions (Figure 6E-F). These findings 
were further confirmed at the protein level through immunohistochemistry for SMAD4 and P-
SMAD3 (Supplemental figure 6A). Notably, the few metastases observed in the miR-527 and 
miR-665 groups express a lower level of SMAD4 and TȕRII respectively compared to the 
miR-ct group, validating their inhibition by miR-527 and miR-665. Correspondingly, 
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immunohistochemistry showed decreased SMAD4 and P-SMAD3 in these specimens 
(Supplemental Figure 6B).  
In keeping with a contribution of this pathway in carcinomas as well as mesenchymal tumors, 
we found a weak but statistically significant inverse correlation between ǻNp63 and miR-527 
in a small cohort of breast tumor specimens (Supplemental figure 6C), and the analysis of a 
larger cohort from GEO reveled again a weak but statistically significant inverse correlation 
between miR-527 and SMAD4 (Supplemental figure 6D).  
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p63, miR-527 and miR-665 regulate a wound healing pathway 
Finally, we sought to discover the normal physiological context for the regulatory network we 
had uncovered. Of immediate interest was wound healing, a biological process involving 
complex regulation of various pathways including cell migration, proliferation and 
extracellular matrix remodeling, generally stimulated by TGFく and recently shown to involve 
〉Np63g (42-45). Thus we asked whether the endogenous 〉Np63g/miR network regulating 
the TGFく pathway we identified was associated with a newly identified pathway controlling 
the normal wound healing response. Recently, TGFく signaling has been described as 
switching off anti-migratory miR-198 expression by downregulating the RNA-binding protein 
KSRP (46). Indeed, KSRP promotes the biogenesis of a subset of microRNAs harboring the 
GUG motif as in miR-198 within its terminal loop (47). Moreover it has been demonstrated 
that phosphorylated R-SMAD proteins, the transducers of TGFく signaling, activate the 
expression of a miR targeting KSRP (46). Supporting the link between our model and the 
wound healing KSRP/miR-198 pathway (Figure 7A), we noted that in our initial microarray 
analysis, shRNA-mediated inhibition of endogenous p63 resulted in a nearly 6-fold 
upregulation of miR-198 (Supplemental Figure 1A). Further supporting this link, we found 
that the expression of KSRP is repressed by the expression of 〉Np63g and increased 
following the expression of both miR-527 and miR-665. In keeping with regulation of this 
wound-healing pathway by the endogenous p63/miR-527/665 circuit, we observed that KSRP 
is up regulated by repression of endogenous p63, while repression of either endogenous miR-
527 or miR-665 with anti-miRs leads to KSRP repression (Figure 7C).  
 
We then validated directly the predicted consequences of these effects on miR-198 
expression. As anticipated, miR-198 is repressed by the expression of 〉Np63g and activated 
after repression of endogenous p63 (Figure 7D). Conversely the overexpression of both miR-
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527 and miR-665 leads to expression of miR-198, while repression of these endogenous miRs 
with anti-miRs led to miR-198 repression (Figure 7E). Thus, the p63/miR-527/665 circuit we 
have discovered is an endogenous regulator of the key wound-healing factors KSRP and miR-
198.  
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Metastatic dissemination of cancer is a complex and context-dependent process that is 
responsible for the vast majority of cancer lethality. Understanding the molecular details of 
this process will thus be critical for developing more effective therapeutics. Here we 
demonstrate that 〉Np63g, the major p63 isoform expressed in the epithelium and squamous 
malignancies including HNSCC, enhances TGFく-dependent metastatic dissemination. This 
effect is mediated through direct inhibition of a miR transcriptional network involving miR-
527 and miR-665. A key novel feature of our work is demonstrating how 〉Np63g functions 
to control cellular microenvironmental cues via TGFく. In contrast to TAp63, which is 
proposed to be controlled by upstream TGFく/SMAD activation (19), we reveal a distinct 
pathway whereby 〉Np63g controls downstream TGFく/SMAD activity. Supporting a selective 
role for 〉Np63g in this mechanism, we provide evidence that this pathway is involved in the 
normal wound healing response, which itself has been linked to 〉Np63g (44,45). Indeed, in 
the context of our orthotopic model we observed substantially increased 〉Np63g expression 
in the metastatic lesions relative to the respective primary tumors, and in advanced squamous 
carcinomas we have shown that 〉Np63g mRNA levels exceed those of TAp63 by up to 200-
fold (48). While multiple mechanisms including clonal selection or epigenetic regulation are 
likely to contribute to selection for 〉Np63g in these distinct contexts, these findings 
collectively point to 〉Np63g as a driver of tumor progression and metastasis. 
 
Our data suggest that in a TGFく-rich microenvironment, 〉Np63g is a pro-metastatic 
transcription factor. This context and isoform-specific effect of 〉Np63g may explain the lack 
of agreement in the literature on the contribution of this p63 isoform to cancer dissemination. 
One study showed that 〉Np63g promotes tumor formation and metastasis through the 
regulation of brachyury expression, an important gene for limb development which is also 
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implicated in both epithelial to mesenchymal transition (EMT) and mesenchymal to epithelial 
transition (MET)(20). Related to the EMT process, 〉Np63g also promotes the expression of 
at least one important mesenchymal marker in bladder cancer as well as accelerates EMT in 
normal human keratinocytes (28). In contrast, other studies have reported p63 and/or 〉Np63g 
as an anti-metastatic factor, through the upregulation of caspase-1 and CD82 for example 
(49,50). Additionally, 〉Np63g was shown to negatively regulate Erk signaling for further 
inhibition of cell migration and invasion in breast cancer (29).  
 
Our study resolves some of these conflicting data by emphasizing the contribution of the 
tumor microenvironment. This is a parameter not accounted for in many studies in the field, 
yet so important for understanding the complexity of metastatic dissemination. Including 
TGFɴ in the equation describing the role of p63 in metastatic dissemination helps clarify this 
role. Accordingly, we performed in vivo validation of our hypothesis in an orthotopic bone 
tumor model for two essential reasons. First, these cells express little or no 〉Np63g, 
providing us opportunity to experimentally introduce this protein in order to study its effects. 
Second and even more importantly, osteosarcoma develops in a bone microenvironment, the 
largest reservoir for TGFく (51). When tumor cells reach bony sites, a ‘vicious cycle’ between 
tumor cells and local bony cells is established resulting in a loss of equilibrium between bone 
resorption and bone matrix deposition. In the case of osteolytic metastatic lesions, the balance 
will bend towards the osteoclastic population leading to a high bone resorption. Degradation 
of bone matrix releases high quantities of cytokines (TGFく and IGF-1), which further enhance 
tumor cell proliferation that in turn will cause more osteolysis and liberation of TGFく, both 
locally and in the general circulation (40). Thus, our findings demonstrate a general 
mechanism whereby 〉Np63g-expressing cells, in a TGFく-rich microenvironment, are 
positively selected during metastatic dissemination owing to the repression of miR-527 and 
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miR-665 and the subsequent upregulation of two major proteins of the TGFく pathway: 
SMAD4 and TくRII. To demonstrate in vivo that the pro metastatic activity of 〉Np63g is 
mediated by the repression of miR-527 and miR-665, another control in vivo experiment 
might be performed where a group of mice injected with 〉Np63g overexpressing cells are 
also treated with miR-527 and miR-665.  
 
Importantly, we provide evidence for the endogenous physiological context in which this 
〉Np63g-mediated pathway normally functions. 〉Np63g is an established mediator of 
epithelial regenerative proliferation that has been, not surprisingly, implicated in the wound 
healing process (44,45). Additionally, it is well established that wound healing involves 
complex regulation of similar pathways as metastatic dissemination, including cell migration 
and extracellular matrix remodeling, generally stimulated by TGFく (42,43). The physiological 
relevance of our findings is therefore strongly supported by our demonstration of the 
connection between the 〉Np63g/miRs network regulating the TGFく pathway on the one 
hand, and TGFく-dependent regulation of wound healing through KSRP/miR-198 on the other. 
By demonstrating the link between this metastatic network and the normal wound healing 
response, this study reveals a new mechanism through which deregulation of p63 may 
contribute to human cancer.  
 
In conclusion, we have uncovered a new microRNAs network regulated by 〉Np63g in the 
context of a TGFɴ-rich microenvironment. This network is involved in the physiological 
regulation of wound healing, but is hijacked by the tumor to disseminate, making our 
discovery relevant in both physiological and pathological contexts. Our study opens some 
potential therapeutic possibilities. For example, miR-527 and miR-665 along with SMAD4 
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and TȕRII expression levels might be used clinically as biomarkers to determine whether or 
not patients are likely to develop metastasis. Ultimately, understanding such metastatic 
regulatory networks should also provide the opportunity for effective therapeutic intervention. 
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Figure 1: p63-regulated microRNAs target the TGFく pathway 
(a) Knockdown of endogenous p63 RNA (top) and protein (bottom) by p63-directed or 
control (Ct) lentiviral shRNA in JHU-029 human SCC cells at 48h. Beta-tubulin (β-Tub) 
serves as a loading control. (b) Array analysis showing the fold-change and direction of 
change for all miRs regulated > 1.5-fold in p63-ablated versus control samples shown in (a). 
miRs predicted to target members of the TGFく pathway are indicated in red. (c) Graphical 
abstract of our working hypothesis. (d) Validation of p63 repression of miRs targeting the 
TGFく pathway, by real-time quantitative RT-PCR (qRT-PCR) at 72 hours post lentiviral p63-
directed or control shRNA expression in JHU-029 cells. (e) Validation of p73 activation of 
miRs targeting the TGFく pathway, by qRT-PCR at 1 and 2 hours post tretracycline treatment 
using a tetracycline-inducible TAp73く JHU-029 human SCC cells. (f) p63/p73 - regulated 
miRs regulate the TGFく pathway. A reporter construct containing the SMAD4 biding motif of 
PAI-1 promoter fused to luciferase was co-transfected with the indicated synthetic miR 
duplexes. Results show relative luciferase units (RLU) normalized to the control reporter 
lacking the SMAD4 biding motif. (g) p63/p73 regulates the TGFく pathway. A reporter 
construct containing the SMAD4 biding motif of PAI-1 promoter fused to luciferase was co-
transfected with the indicated p63 and p73 isoforms. Results show relative luciferase units 
(RLU) normalized to the control reporter lacking the SMAD4 binding motif. All error bars 
show s.e.m. for triplicate measurements from representative experiments. * p< 0.05, ** p< 
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Figure 2: miR-527 and miR-665 repress Smad4 and TくRII, respectively 
(a) miRs 527 and 665 repress gene expression via SMAD4 and TȕRII 3ガ UTRs, respectively. 
This repression is lost when mutant seed sequences are introduced. Co-transfection of the 
indicated miR mimics or control (ct) miR, together with the UTR-reporter, mutated UTR-
reporter or control reporter; results show relative luciferase units (RLU) normalized to the 
control miR. (fg indicates fragment; SMAD4 3’UTR was too large to be cloned in a single 
construct). One-way ANOVA followed by Dunnett’s multiple comparison tests were used, * 
p< 0.05. (b) qRT–PCR for SMAD4 and TȕRII RNA levels in 48h miR-transfected JHU-029 
cell line. (c) JHU-029 cells were transfected with anti-miR ct (controls) or anti-miR 
candidates (anti-miR 527 and anti-miR 665) and SMAD4 and TくRII expression levels were 
evaluated by western blotting 48h after transfection. Densitometry measurements are 
indicated. (d) Immunoblotting for P-SMAD3 and SMAD3 from JHU-029 cells transfected 
with pre/anti miR ct (controls) or pre/anti miRs candidates (pre/anti-miR 527 and pre/anti-
miR 665). Cells were treated or not with 5ng/mL TGFく for 15 minutes. All error bars show 
s.e.m. for triplicate measurements from representative experiments. 
 
Figure 3: p63 and p73 regulate SMAD4 and TくRII  
(a) mRNA expression of indicated key members of the TGFく pathway analyzed over time by 
qRT-PCR after induction of TAp73く by a tetracycline inducible system in the JHU-029 cell 
line. (b) qRT-PCR for the indicated key members of the TGFく pathway in JHU-029 after 48h 
of transfection with pcDNA3 (control) or pcDNA3 〉Np63g. * p< 0.05, ** p< 0.01, *** p< 
0.001. Two-way ANOVA followed by Tukey’s multiple comparison tests were used. (c) 
Immunoblotting for SMAD3 and P-SMAD3 in JHU-029 after 48h of transfection with 
TAp73く and shRNA for p63 with their respective controls. Cells were treated or not with 
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5ng/mL TGFく for 15 minutes to show lower activation of the TGFく pathway. p63, p73, 
SMAD4 and TくRII protein levels were analyzed in JHU-029 cells after 48h of transient 
overexpression of TAp73く or knockdown of p63 using shRNA. Densitometry measurements 
are indicated. All error bars show s.e.m. for triplicate measurements from representative 
experiments. 
 
Figure 4: The p63 and p73-controlled miR network regulates TGFく induced migration 
(a) JHU-029 cells were transfected with indicated miR mimics or with control. 24h later cells 
were treated or not with TGFく (5ng/mL) and were re-treated before the migration test. (b) 
JHU-029 cells were transfected with TAp73く, 〉Np63g or pcDNA3 (control). Cells were 
treated or not with TGFく (5ng/mL) 24h later and re-treated before the migration test. 
Migrated cells were counted after 24h of migration in boyden chambers. Migrated cells were 
counted after 24h of migration in boyden chambers. * p< 0.05, ** p< 0.01, *** p< 0.001. 
Two-way ANOVA followed by Tukey’s multiple comparison tests were used. All error bars 
show s.e.m. for triplicate measurements from representative experiments. (c) Scratch assay 
was performed 48h after transfection of JHU-029 cells with TAp73く, 〉Np63g or pcDNA3 
(control), prior to a 24h TGFく treatment (or not) at 5ng/mL. (d, e) The same scratch assay was 
performed 48h after transfection of the indicated miR mimics/anti-miRs or with controls.  
 
Figure 5: p63 induces TGFく-mediated metastasis in vivo 
(a) Overexpression of 〉Np63g mRNA (top) and protein (bottom) in 〉Np63g-HOS group vs 
control group. (b) HOS cells were transfected with 〉Np63g or control vectors and treated or 
not with TGFく (5ng/mL) after 24h. Cell migration (left) and invasion (right) were analyzed 
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after 24h. Results are expressed in terms of cell-occupied area vs total area. Two-way 
ANOVA followed by Tukey’s multiple comparison tests were used (*** p< 0.001). (c) 
Tumor progression was calculated with the formula (t2 x l)/2 where t is the tumor thickness 
and l is the tumor length. Average tumor volumes for 〉Np63g or control groups over time are 
represented in the graph. Mann-Whitney statistical test was used. (d) Number of metastasis 
found at tumor volume endpoint (2500mm3) for each mouse and average for 〉Np63g or 
control groups. Lung images were obtained after sacrifice showing the difference in 
appearance of the 〉Np63g metastasis vs the control group. Arrows indicate metastatic foci. 
Mann-Whitney statistical test was used. (e) ǻNp63Į, (f) miR-527, miR-665, (g) TȕRII and 
SMAD4 expression levels were analyzed by qRT-PCR in the indicated groups (primary 
tumors PT, metastasis MET, primary tumors that did not produce metastasis (Non met-PT) 
and that did (Met-PT)). All error bars show s.e.m. for triplicate measurements from 
representative experiments. 
 
Figure 6: miR-527 and miR-665 regulate metastasis dissemination in vivo 
(a) Experimental schema. 1.5M HOS LucF GFP were injected paratibially in nude mice. At 
200mm3 tumor volume mice were treated every 48h with 50nM pre-miR control (miR ct-
group), pre-miR-527 (miR-527 group) or pre-miR-665 (miR-665 group). (b) Tumor 
progression was calculated as in Fig. 5. Average tumor volumes for miR-527, miR-665 or 
control groups over time are represented in the graph. Kruskal-Wallis test followed by 
Dunnett’s multiple comparison test were used. (c) Average number of metastasis found at 
tumor volume endpoint (2500mm3) for miR-527, miR-665 or control groups. Mann-Whitney 
statistical test was used. * p< 0.05. (d) Bioluminescence imaging of lungs after sacrifice for 
miR-527, miR-665 and control groups. (e) miR-527 and SMAD4 expression levels were 
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analyzed by qRT-PCR. (f) miR-665 and TȕRII expression levels were analyzed by qRT-PCR. 
All error bars show s.e.m. for triplicate measurements from representative experiments. 
 
Figure 7: p63, miR-527 and miR-665 regulate a wound-healing pathway 
(a) Schematic representation of the interplay between the p63/miR-527/miR-665 pathway and 
the wound healing KSRP/miR-198 pathway. (b) KSRP expression level analyzed by qRT-
PCR after 48h overexpression of 〉Np63g or shRNA against p63 and their respective controls 
in HOS cells and 029 cells, respectively. (c) Expression of the pre-miR-527, pre-miR-665, 
anti-miR-527, anti-miR-665 and their controls. (d) miR-198 expression level analyzed by 
qRT-PCR after 48h overexpression of 〉Np63g or shRNA against p63 and their respective 
controls in HOS cells and 029 cells, respectively. (e) Expression of the pre miR-527, pre-miR-
665, anti-miR-527, anti-miR-665 and their respective controls. All error bars show s.e.m. for 
triplicate measurements from representative experiments. 
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From 8 mice per group: 
-Metastasis incidence in control group: 1/8= 12.5%. 
-Metastasis incidence in 〉Np63g group: 6/8= 75%. 
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